Intracerebroventricular infusion of donepezil prevents cardiac remodeling and improves the prognosis of chronic heart failure rats

DOI PDF Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献3件 参考文献43件 オープンアクセス

書誌事項

公開日
2020
資源種別
journal article
権利情報
  • https://www.elsevier.com/tdm/userlicense/1.0/
  • https://www.elsevier.com/legal/tdmrep-license
  • http://creativecommons.org/licenses/by/4.0
DOI
  • 10.1186/s12576-020-00739-0
公開者
Elsevier BV

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Oral administration of donepezil, a centrally acting acetylcholinesterase inhibitor, improves the survival of rats with chronic heart failure (CHF). The mechanisms of cardioprotective effects of donepezil, however, remain totally unknown. To elucidate potential mechanisms, we examined whether central microinfusion of donepezil would exert cardioprotection. Intracerebroventricular microinfusion pumps with cerebroventricular cannula were implanted in rats with myocardial infarction. The rats were randomly divided into central saline treatment (CST) and central donepezil treatment (CDT) groups. We evaluated cardiac remodeling and function after a 6-week treatment and examined the 160-day survival rate. Compared to the CST, the CDT markedly improved the 160-day survival rate (68% vs. 32%,<jats:italic>P</jats:italic> = 0.002) through the prevention of cardiac remodeling and the lowering of plasma catecholamine, brain natriuretic peptide, and angiotensin II. These results suggest that the central mechanism plays an important role in the cardioprotective effects of donepezil.</jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (43)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

問題の指摘

ページトップへ